诺和诺德的“救援”：与Aspect Biosystems深化合作，推进糖尿病细胞疗法研发

药研界面01-21

美东时间1月20日，诺和诺德与Aspect Biosystems宣布双方合作进入新阶段，共同开发用于糖尿病治疗的先进细胞药物。自2023年起，Aspect与诺和诺德便开始合作研发细胞药物，旨在替代、修复或补充生物功能，以实现真正的疾病修饰疗法。此次合作成果推进，加速了双方研发重疾病药物的共同使命。根据合作协议，Aspect获得了诺和诺德的干细胞衍生胰岛细胞及低免疫细胞工程技术的相关权利，并将主导这...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2605780151?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-21 14:13","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2605780151","market":"us","top_or_hot":-1,"title":"诺和诺德的“救援”：与Aspect Biosystems深化合作，推进糖尿病细胞疗法研发","media":"药研界面","content":"<div>\n<p>美东时间1月20日，诺和诺德与Aspect Biosystems宣布双方合作进入新阶段，共同开发用于糖尿病治疗的先进细胞药物。自2023年起，Aspect与诺和诺德便开始合作研发细胞药物，旨在替代、修复或补充生物功能，以实现真正的疾病修饰疗法。此次合作成果推进，加速了双方研发重疾病药物的共同使命。根据合作协议，Aspect获得了诺和诺德的干细胞衍生胰岛细胞及低免疫细胞工程技术的相关权利，并将主导这...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121141927a69afa60&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德的“救援”：与Aspect Biosystems深化合作，推进糖尿病细胞疗法研发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德的“救援”：与Aspect Biosystems深化合作，推进糖尿病细胞疗法研发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-21 14:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121141927a69afa60&s=b><strong>药研界面</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美东时间1月20日，诺和诺德与Aspect Biosystems宣布双方合作进入新阶段，共同开发用于糖尿病治疗的先进细胞药物。自2023年起，Aspect与诺和诺德便开始合作研发细胞药物，旨在替代、修复或补充生物功能，以实现真正的疾病修饰疗法。此次合作成果推进，加速了双方研发重疾病药物的共同使命。根据合作协议，Aspect获得了诺和诺德的干细胞衍生胰岛细胞及低免疫细胞工程技术的相关权利，并将主导这...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121141927a69afa60&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121141927a69afa60&s=b","article_id":"2605780151","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121141927a69afa60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605780151","pubTimestamp":1768976002,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"美东时间1月20日，诺和诺德与Aspect Biosystems宣布双方合作进入新阶段，共同开发用于糖尿病治疗的先进细胞药物。自2023年起，Aspect与诺和诺德便开始合作研发细胞药物，旨在替代、修复或补充生物功能，以实现真正的疾病修饰疗法。诺和诺德将向Aspect追加股权投资，并提供研究资金，以推动这些潜在治愈性疗法的研发进程。同时，诺和诺德将有资格从Aspect未来的产品销售中获得特许权使用费及里程碑付款。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4599":"减肥药","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","NVO":"诺和诺德"},"translate_title":"Novo Nordisk's \"rescue\": deepening cooperation with Aspect Biosystems to promote the research and development of diabetic cell therapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.95},"content_text":"美东时间1月20日，诺和诺德与Aspect Biosystems宣布双方合作进入新阶段，共同开发用于糖尿病治疗的先进细胞药物。自2023年起，Aspect与诺和诺德便开始合作研发细胞药物，旨在替代、修复或补充生物功能，以实现真正的疾病修饰疗法。此次合作成果推进，加速了双方研发重疾病药物的共同使命。根据合作协议，Aspect获得了诺和诺德的干细胞衍生胰岛细胞及低免疫细胞工程技术的相关权利，并将主导这类疗法的研发、生产与商业化工作。诺和诺德将向Aspect追加股权投资，并提供研究资金，以推动这些潜在治愈性疗法的研发进程。同时，诺和诺德将有资格从Aspect未来的产品销售中获得特许权使用费及里程碑付款。双方达成的协议还包括，将诺和诺德在美国和丹麦的部分细胞疗法研发、生产能力及专业知识，整合至Aspect以加拿大为基地的平台中。这一整合将强化Aspect的端到端服务能力，并助力其吸纳更多高素质专业人才。Aspect 是一家专注于开发新型细胞药物的生物技术公司，其核心是全栈组织治疗平台，该平台整合了专有的AI驱动生物打印技术、治疗细胞、低免疫细胞工程及先进生物材料。目前，其平台正用于开发针对严重代谢与内分泌疾病的疗法，其中领先项目是一款针对1型糖尿病的胰岛替代疗法。该疗法设计为异基因（现成）疗法，目标是在无需长期免疫抑制的情况下恢复患者的血糖控制，并实现规模化生产。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605780151","isCrawlerRequest":true}